+ Watch CYCC
on My Watchlist
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Cyclacel is carving out a new spike this month, undoubtedly related to ASCO's approach. But the company's presentations are unlikely to contain meaningful new data - the SEAMLESS phase III trial of sapacitabine in elderly AML was only initiated a few months ago. After ASCO, investors will have to confront a company with a pipeline comprised of two weak candidates. Seliciclib may vanish from the scene after topline results of the APPRAISE phase IIb trial showed no effect of progression-free survival and only a non-significant positive trend in overall survival. Meanwhile, the phase II data for sapacitabine in elderly AML was unimpressive - 30% one-year survival, which compares unfavorably to the 40% one-year survival reported for Vidaza in an earlier study. Only interim safety data for SEAMLESS is expected in 2011. Another dilutive financing is almost certain before SEAMLESS proceeds to completion.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions